WATER IV PCa (AS Sub-study)
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The WATER IV AS sub-study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with low to intermediate risk localized prostate cancer who are candidates for active surveillance. Participants will be randomized to either Aquablation Therapy or active surveillance and followed up to 10 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Angela Lee
- Telefonnummer: 650-232-7215
- E-mail: a.lee@procept-biorobotics.com
Studiesteder
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85224
- Ikke rekrutterer endnu
- Arizona State Urological Institute
-
Ledende efterforsker:
- Pratik Patel, MD
-
Kontakt:
- Dianna Baldanado
- E-mail: dbaldonado@asuri.net
-
-
California
-
Los Angeles, California, Forenede Stater, 90089
- Rekruttering
- University of Southern California
-
Ledende efterforsker:
- Inderbir Gill, MD
-
Ledende efterforsker:
- Mihir Desai, MD
-
Kontakt:
- Ileana Aldana
- Telefonnummer: (323) 865-0702
- E-mail: Nohely.Aldana@med.usc.edu
-
Murrieta, California, Forenede Stater, 92562
- Ikke rekrutterer endnu
- Tri Valley Urology
-
Kontakt:
- Anita Deeds
- Telefonnummer: 232 951-698-1901
- E-mail: anita@trivalleyurology.net
-
-
Colorado
-
Boulder, Colorado, Forenede Stater, 80304
- Ikke rekrutterer endnu
- Boulder Medical Center
-
Kontakt:
- Stephanie Leonard
- E-mail: sleonard@westernstatesncorp.org
-
-
Florida
-
Delray Beach, Florida, Forenede Stater, 33484
- Rekruttering
- Advanced Research
-
Ledende efterforsker:
- Christopher Tallman, MD
-
Kontakt:
- Julia Conceição
- Telefonnummer: (954)-302-3163
- E-mail: jconceicao@advancedresearchfl.com
-
Miami, Florida, Forenede Stater, 33146
- Ikke rekrutterer endnu
- University of Miami
-
Ledende efterforsker:
- Bruno Nahar, MD
-
Kontakt:
- Laura Ochoa
- E-mail: lxo315@med.miami.edu
-
Tampa, Florida, Forenede Stater, 33607
- Ikke rekrutterer endnu
- Trophy Point Urology
-
Kontakt:
- Zachary Finley
- E-mail: zfinley@floridaurologypartners.com
-
Ledende efterforsker:
- Timothy Weber, MD
-
Underforsker:
- Jonathan Pavlinec, MD
-
Underforsker:
- David Hochberg, MD
-
Underforsker:
- Drew Palmer, MD
-
Underforsker:
- Sam Fisher, MD
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30328
- Rekruttering
- Georgia Urology
-
Ledende efterforsker:
- Lewis Kriteman, MD
-
Kontakt:
- Cyprian Adi
- Telefonnummer: 404-292-3727
- E-mail: Cyprian.adi@gaurology.com
-
Underforsker:
- Froylan Gonzalez, MD
-
-
Idaho
-
Idaho Falls, Idaho, Forenede Stater, 83401
- Rekruttering
- Mountain View Hospital
-
Kontakt:
- Morgann Torres
- E-mail: mtorres1@mvhospital.net
-
Ledende efterforsker:
- Jared Manwaring, MD
-
Underforsker:
- Richard Blatter, MD
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Ikke rekrutterer endnu
- University of Chicago
-
Kontakt:
- Briana Harrison
- E-mail: bharrison1@bsd.uchicago.edu
-
Glenview, Illinois, Forenede Stater, 60026
- Rekruttering
- Endeavor Health
-
Underforsker:
- Alexander Glaser, MD
-
Kontakt:
- Pooja Talaty
- E-mail: pooja.talaty@endeavorhealth.org
-
Ledende efterforsker:
- James Kearns, MD
-
Underforsker:
- Brian Helfand, MD
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Ikke rekrutterer endnu
- Johns Hopkins University
-
Ledende efterforsker:
- Arun Rai, MD
-
Kontakt:
- George Metri
- E-mail: gmetri1@jh.edu
-
Underforsker:
- Arvin George, MD
-
-
Missouri
-
North Kansas City, Missouri, Forenede Stater, 64116
- Ikke rekrutterer endnu
- Kansas City Urology Care
-
Kontakt:
- Judy Searcy
- Telefonnummer: 913-647-4173
- E-mail: jsearcy@kcuc.com
-
Ledende efterforsker:
- Gerald Park, MD
-
Underforsker:
- Patrick Probst, MD
-
-
Nebraska
-
Kearney, Nebraska, Forenede Stater, 68847
- Rekruttering
- Kearney Urology Center
-
Ledende efterforsker:
- Garrett Pohlman, MD
-
Kontakt:
- Monique Pohlman
- E-mail: water4trialkearneyurology@gmail.com
-
Omaha, Nebraska, Forenede Stater, 68114
- Rekruttering
- Adult & Pediatric Urology
-
Ledende efterforsker:
- Andrew Trainer, MD
-
Kontakt:
- Christian Valverde
- E-mail: cvalverde@urohealthpartners.com
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Ikke rekrutterer endnu
- Hackensack University Medical Center
-
Ledende efterforsker:
- Nitin Yerram, MD
-
Kontakt:
- Oncology Clinical Research Referral Office
- Telefonnummer: 551-996-1777
- E-mail: OncologyResearchReferral@hmhn.org
-
Underforsker:
- Ravi Munver, MD
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Ikke rekrutterer endnu
- Albany Medical College
-
Ledende efterforsker:
- Ronald Kaufman, MD
-
Kontakt:
- Brenda Romeo
- Telefonnummer: (518) 262-8579
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Integrated Medical Professionals, PLLC
-
Ledende efterforsker:
- Jed Kaminetsky, MD
-
Ledende efterforsker:
- Alexander Epelbaum, MD
-
Ledende efterforsker:
- Gary Goldberg, MD
-
Kontakt:
- Michael Yang
- E-mail: myang@imppllc.com
-
Rochester, New York, Forenede Stater, 14642
- Ikke rekrutterer endnu
- University of Rochester Medical Center
-
Kontakt:
- Caitlyn Michelsen
- E-mail: Caitlyn_Michelsen@URMC.Rochester.edu
-
Ledende efterforsker:
- Thomas Frye, MD
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Ikke rekrutterer endnu
- Cleveland Clinic Foundation
-
Ledende efterforsker:
- Petar Bajic, MD
-
Kontakt:
- Lauren Grimm
- Telefonnummer: 216-444-4650
- E-mail: grimml@ccf.org
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Rekruttering
- MUSC Hollings Cancer Center
-
Ledende efterforsker:
- Eric Wallen, MD
-
Kontakt:
- Sarah Helpinstill
- Telefonnummer: 843-792-9300
- E-mail: sah277@musc.edu
-
Murrells Inlet, South Carolina, Forenede Stater, 29576
- Ikke rekrutterer endnu
- Tidelands Health Urology
-
Kontakt:
- Barbara Roe
- E-mail: broe@tidelandshealth.org
-
Ledende efterforsker:
- Lauren Cooley, MD
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Rekruttering
- Urology Austin
-
Ledende efterforsker:
- Brian Mazzarella, MD
-
Kontakt:
- Jennifer Penshorn, RN
- E-mail: jennifer.penshorn@urologyaustin.com
-
Underforsker:
- David Cuellar, MD
-
Underforsker:
- Eric Giesler, MD
-
Underforsker:
- Varun Sundaram, MD
-
Underforsker:
- Carl Bischoff, MD
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Midtown Urology
-
Kontakt:
- Andrew Barger
- Telefonnummer: 512-451-7935
- E-mail: APBarger@cimplify.net
-
Ledende efterforsker:
- Michael Trotter, MD
-
Underforsker:
- Tyler McClintock, MD
-
Dallas, Texas, Forenede Stater, 75231
- Rekruttering
- Urology Clinics of North Texas
-
Ledende efterforsker:
- Gregory Thoreson, MD
-
Kontakt:
- Jacquelyn Ward
- E-mail: jward@urologyclinics.com
-
-
Virginia
-
Alexandria, Virginia, Forenede Stater, 22311
- Ikke rekrutterer endnu
- Potomac Urology
-
Ledende efterforsker:
- Shawn Marhamati, MD
-
Underforsker:
- Nilay Gandhi, MD
-
Kontakt:
- Zoe Goldstein
- E-mail: zoe.goldstein@potomacurology.com
-
-
Wisconsin
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Ikke rekrutterer endnu
- Advocate Aurora Research Institute
-
Ledende efterforsker:
- Jeffrey Tomasini, MD
-
Kontakt:
- Mary Theodoroff
- E-mail: mary.theodoroff@aah.org
-
-
-
-
-
Shatin, Hong Kong
- Ikke rekrutterer endnu
- Chinese University of Hong Kong
-
Kontakt:
- Becky Lau
- E-mail: beckylau@surgery.cuhk.edu.hk
-
Ledende efterforsker:
- Jeremy Teoh, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Biological male with age ≥ 45 years at the time of consent
- Biopsy positive Grade Group 2 prostate cancer or biopsy positive Grade Group 1 MRI visible lesion (PI-RADS/Likert ≥ 3)
- First prostate cancer diagnoses within 18 months (545 days) of consent
- Are candidates for active surveillance
- Clinical Stage ≤ T2c
- PSA < 15 ng/ml
- Prostate volume ≥25 ml
Exclusion Criteria:
- Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
- Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
- Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
- Patient is unwilling to accept a blood transfusion if required.
- Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:
5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).
6. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
7. Patient currently participating in other studies unless approved by Sponsor in writing.
8. More than one complete biopsy beyond the diagnostic biopsy comprising both a systematic biopsy and biopsy of any MRI visible lesion (PI-RADS/Likert ≥ 3).
9. GG2 disease with PSA ≥ 10 OR stage ≥ T2b OR ≥ 50% of biopsy cores positive (multiple cores taken from any MRI visible lesion are counted as one continuous core).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Aquablation Therapy
The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System |
The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy. |
|
Aktiv komparator: Active Surveillance
The active surveillance arm will receive standard-of-care for prostate cancer management. |
Active surveillance is a management strategy for men with low- and favorable intermediate-risk localized prostate cancer that involves close monitoring with curative intent, reserving treatment for evidence of disease progression. Monitoring typically includes serial PSA testing, periodic prostate MRI, and repeat biopsies at scheduled intervals, with intervention triggered by evidence of disease progression. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Freedom from GG ≥ 2
Tidsramme: 12 Months
|
12 Months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Freedom from persistent or increased MRI suspicion AND additional prostate cancer treatment
Tidsramme: 3 Years
|
3 Years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Genitale neoplasmer, mandlige
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Kønssygdomme, mandlige
- Prostatasygdomme
- Mandlige urogenitale sygdomme
- Prostatiske neoplasmer
- Sundhedstjenester Administration
- Sundhedskvalitet
- Resultatvurdering, sundhedsvæsen
- Resultat og procesvurdering, sundhedsvæsen
- Vågn venter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CSP0005 - AS Sub-study
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .